Categories
Publications

“He who pays the piper calls the tune”: Researcher experiences of funder suppression of health behaviour intervention trial findings – PLOS ONE

Background
Governments commonly fund research with specific applications in mind. Such mechanisms may facilitate ‘research translation’ but funders may employ strategies that can also undermine the integrity of both science and government. We estimated the prevalence and investigated correlates of funder efforts to suppress health behaviour intervention trial findings.

Conclusions
One in five researchers in this global sample reported being pressured to delay, alter, or not publish the findings of health behaviour intervention trials. Regulation of funder and university practices, establishing study registries, and compulsory disclosure of funding conditions in scientific journals, are needed to protect the integrity of public-good research.

http://archive.today/2021.08.26-220224/https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0255704

Categories
News

Health researchers report funder pressure to suppress results – Nature

Government agencies such as health departments might be more inclined to intervene if findings from a study they commissioned are not as expected or if they are heavily invested in the health intervention — such as an education or health programme — being trialled, she adds.

A 2016 inquiry into the delayed publication of research commissioned by UK government agencies identified cases in which publication was “manipulated to fit with political concerns”. More recently, the British Medical Journal reported four instances of politicization and suppression of science in the United Kingdom during the COVID-19 pandemic.

http://archive.today/2021.08.20-134039/https://www.nature.com/articles/d41586-021-02242-x

Categories
Publications

Risk in Vaccine Research and Development Quantified – PLOS ONE

Published in 20th March 2013

A database was actively compiled to include all vaccine projects in development from 1998 to 2009 in the pre-clinical development phase, clinical trials phase I, II and III up to Market Registration. The average vaccine, taken from the preclinical phase, requires a development timeline of 10.71 years and has a market entry probability of 6%. Stratification by disease area reveals pandemic influenza vaccine targets as lucrative.

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0057755

Categories
Publications

Vitamin D sufficiency, a serum 25-hydroxyvitamin D at least 30 ng/mL reduced risk for adverse clinical outcomes in patients with COVID-19 infection – PLOS ONE

…it is recommended that improving vitamin D status in the general population and in particular hospitalized patients has a potential benefit in reducing the severity of morbidities and mortality associated with acquiring COVID-19.

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0239799